Allopurinol and Intima-Media Thickness - Pilot phase

This double blind placebo controlled randomised clinical trial is evaluating the effect of a one year course of allopurinol 300 mg once daily on carotid intima media thickness progression rate, endothelial function and levels of endothelial progenitor cells in patients with recent stroke. Eighty participants will be randomised to allopurinol 300 mg per day or placebo on a 1:1 basis.
The study is funded by the UK Stroke Association and will be completed in 2012 and report in mid 2012. A definitive clinical endpoint study in this patient group will hopefully follow.